ArticlePharmaceuticals (Basel, Switzerland)2016
Therapeutic Potential of Gramicidin S in the Treatment of Root Canal Infections.
Article in Pharmaceuticals (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 39 citations in OpenAlex.
- The Diverse Activities and Mechanisms of the Acylphloroglucinol Antibiotic Rhodomyrtone: Antibacterial Activity and Beyond.Antibiotics (Basel, Switzerland) · 2024Review
- Antimicrobial peptide-based strategies to overcome antimicrobial resistance.Archives of microbiology · 2024Review
- Modifying Membranotropic Action of Antimicrobial Peptide Gramicidin S by Star-like Polyacrylamide and Lipid Composition of Nanocontainers.International journal of molecular sciences · 2024Article
- Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection.Scientific reports · 2022Article
- A flat embedding method for transmission electron microscopy reveals an unknown mechanism of tetracycline.Communications biology · 2021Article
- Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.Frontiers in cellular and infection microbiology · 2021Review
- An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections.Pharmaceutics · 2020Review
- Supreme activity of gramicidin S against resistant, persistent and biofilm cells of staphylococci and enterococci.Scientific reports · 2019Article
- Article
- Antimicrobial peptides produced by Brevibacillus spp.: structure, classification and bioactivity: a mini review.World journal of microbiology & biotechnology · 2018Review
- Host defense antimicrobial peptides as antibiotics: design and application strategies.Current opinion in chemical biology · 2017Review
- Antimicrobial peptide gramicidin S is accumulated in granules of producer cells for storage of bacterial phosphagens.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An intrinsic clindamycin-resistant Enterococcus faecalis, the most common single species present in teeth after failed root canal therapy, often possesses acquired tetracycline resistance. In these cases, root canal infections are commonly treated with Ledermix(®) paste, which contains demeclocycline, or the new alternative endodontic paste Odontopaste, which contains clindamycin; however, these treatments are often ineffective. We studied the killing activity of the cyclic antimicrobial peptide gramicidin S (GS) against planktonic and biofilm cells of tetracycline-resistant clinical isolates of E. faecalis. The high therapeutic potential of GS for the topical treatment of problematic teeth is based on the rapid bactericidal effect toward the biofilm-forming, tetracycline-resistant E. faecalis. GS reduces the cell number of planktonic cells within 20-40 min at a concentration of 40-80 μg/mL. It kills the cells of pre-grown biofilms at concentrations of 100-200 μg/mL, such that no re-growth is possible. The translocation of the peptide into the cell interior and its complexation with intracellular nucleotides, including the alarmon ppGpp, can explain its anti-biofilm effect. The successful treatment of persistently infected root canals of two volunteers confirms the high effectiveness of GS. The broad GS activity towards resistant, biofilm-forming E. faecalis suggests its applications for approval in root canal medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.